Part 2 of Our AFP Intelligence Series: The Hidden Threat to Specialty Brand Revenue & Patient Care
AFPs operate as coordinated workflows—not isolated programs—redirecting patients, reshaping access pathways, and shifting financial responsibility in ways that are difficult to detect through traditional data.
Alternate funding programs (AFPs) are employer-driven strategies designed to reduce specialty drug costs by redirecting commercially insured patients into alternate access pathways—most often manufacturer-funded Patient Assistance Programs (PAPs) and charitable foundations.
In practice, this means patients who would typically access therapy through their commercial insurance are instead routed into non-commercial channels, shifting financial responsibility away from the employer and onto manufacturer-funded programs.
But AFPs don’t operate as a single intervention. They are sophisticated, integrated systems designed to identify high-cost patients early, redirect their access pathways, and systematically reshape how therapy is accessed and funded.
In Part 1 of this blog series, we explored how AFPs emerged and why they matter now. The next question is more operational: how do these programs work in practice?
To answer that, it’s helpful to break AFPs down into three layers:
- The step-by-step patient journey
- The ecosystem of organizations that enable it
- The tactics used to move patients through alternate pathways
Together, these layers form a system that operates largely out of sight—but with significant implications for access, economics, and data visibility.
The AFP Workflow: Step by Step
While AFP programs vary in design, most follow a consistent sequence.
Step 1: Patient Identification and Triage
AFP vendors receive pharmacy claims data—typically from the employer’s pharmacy benefit manager (PBM). Using proprietary algorithms, they identify patients who are prescribed or actively filling high-cost specialty drugs, often above a defined annual threshold.
These patients are then targeted for outreach, typically framed as a cost-saving or enhanced support program.
Step 2: Benefit Suspension or Exclusion
After a patient is identified, the employer plan may suspend, coordinate around, or formally exclude coverage for the specific drug.
In more advanced models, the plan is intentionally designed so the drug is not covered under the commercial benefit at all—leaving AFP enrollment as the primary pathway to access.
Step 3: Enrollment in Assistance Pathways
With commercial coverage removed or limited, the AFP vendor facilitates enrollment into:
- Manufacturer Patient Assistance Programs (PAPs)
- Independent charitable foundations
- A combination of both
From the manufacturer’s perspective, the patient appears eligible for assistance. In reality, the patient is commercially insured, but their coverage has been engineered out of the pathway.
Step 4: Copay Assistance Exploitation
In some cases, AFP programs layer in copay assistance strategies—using manufacturer copay cards, either alongside or prior to PAP enrollment, to extract additional value before transitioning fully to free goods.
At this point, the patient is receiving therapy, but through a fundamentally different financial and operational pathway than a standard commercial fill.
The AFP Ecosystem: Who Enables It
This workflow does not operate in isolation. It is supported by a network of stakeholders, each playing a distinct role.
Core Participants
- AFP vendors
Organizations that design and operate the core program, including patient identification, benefit coordination, and enrollment workflows. - Copay maximizer and accumulator program vendors
Programs that capture manufacturer copay assistance value, often intersecting with AFP workflows. - Specialty pharmacy partners
Pharmacies that dispense therapy within AFP-aligned channels, often separate from manufacturer-preferred networks. - Independent patient assistance foundations
These legitimate nonprofit organizations help underinsured and financially distressed patients access medications. They are not AFP vendors and do not participate in AFP programs as knowing co-conspirators. However, AFP operators exploit these foundations by routing commercially insured patients—whose employers have excluded the target drug—into these programs, misrepresenting or obscuring their true insurance status. The foundations become unwitting conduits for AFP cost-shifting. Manufacturer donations to these foundations indirectly fund the employer savings generated by AFP programs. - International procurement channels
International drug procurement—sourcing FDA-approved drugs or their international equivalents from Canadian, European, or other foreign pharmacies—represents a distinct and growing branch of the AFP ecosystem. These programs exploit the significant price differential between U.S. WAC prices and the price-controlled or negotiated prices available in other countries. While federal law generally prohibits commercial importation of prescription drugs, FDA enforcement discretion policies, state-level importation programs, and the practical reality of international mail-order operations have created an environment in which these programs operate with varying degrees of legality and risk. - Benefits consultants and advisory firms
Benefit consulting firms and pharmacy benefit advisors are a critical enabler of AFP deployment at scale. They do not operate AFP programs directly, but they serve as the primary channel through which self-insured employers learn about, evaluate, and implement AFP strategies. These firms earn performance-based fees, advisory retainers, or revenue-share arrangements that create economic incentives aligned with AFP adoption.
Each of these participants may operate independently. Together, they form a system that enables AFP workflows to scale across employers, therapeutic categories, and patient populations.
The Tactics Behind AFP Workflows
Understanding the AFP vendor landscape is only part of the picture. The mechanics through which these vendors deploy cost mitigation are also important.
Common AFP Methodologies
- Direct enrollment of commercially insured patients into manufacturer PAPs
- Routing patients through independent charitable foundations
- International or alternative pharmacy sourcing for eligible therapies
- Use of copay accumulator and maximizer programs
- Plan benefit exclusion engineering to remove commercial coverage
- Exploitation of the 340B Drug Pricing Program, which requires manufacturers to provide outpatient drugs to eligible covered entities such as federally qualified health centers, certain hospitals, and clinics at deeply discounted prices
- White-bagging for infusible specialty drugs, in which medications are dispensed to the site of care (hospital infusion center or physician’s office) by a payer-selected specialty pharmacy, rather than being acquired by the provider through traditional channels. Brown-bagging refers to the patient themselves receiving the drug from a payer-selected pharmacy and physically bringing it to the infusion site.
- Site-of-care shifting, in which payers redirect patients receiving specialty drug infusions in high-cost settings such as hospitals to lower-cost alternative sites
- Sequencing strategies that exhaust copay assistance before transitioning to free goods
- Real-time pharmacy benefit checking, which allows AFP vendors to identify and route patients at the moment of prescription dispensing
- Step therapy, or fail-first protocols, which AFP vendors use to guide patients into AFP pathways
- Biosimilar substitution strategies that use mandatory biosimilar preferencing to shift patients off reference biologics
- Out-of-network and cash-pay routing for price arbitrage
- Exploitation of clinical trials and expanded access programs
- Exploitation of specialty drug sampling and free trial supply programs
- Exploitation of workers’ compensation, auto insurance, and carve-out programs
These tactics are not always deployed together—but they are often combined in ways that maximize cost avoidance for the employer while increasing complexity for patients and manufacturers.
Why This System Is So Difficult to See
Understanding how AFPs work behind the scenes also helps explain why they are so difficult to detect.
Each step in the process generates data—but that data is fragmented across different systems:
- Pharmacy dispensing records
- PAP enrollment data
- Foundation assistance records
- PBM claims data
No single source captures the full picture. At the same time, the patient experience often appears normal on the surface. Prescriptions are filled, therapy continues. There is no obvious signal that the access pathway has changed. The result is a system that operates in plain sight—but not in a way that is readily apparent to standard commercial analytics.
Looking Ahead
AFPs are not just changing who pays for therapy. They are reshaping how patients enter the access pathway, how therapy is delivered, and how performance is measured.
In the next blog, we will shift focus to the patient experience—examining how AFP workflows introduce delays, confusion, and fragmentation that often go unmeasured.
